In vitro and in vivo demonstrate that aptamer-modified NPs not only have a specific killing effect on CD113+ osteosarcoma cells, but also have a targeted therapeutic effect on osteosarcoma xenograft mice (Ni et al., 2015). This evidence concerns the gene NECTIN3 and osteosarcoma.